Scagliotti Giorgio Vittorio, Selvaggi Giovanni
University of Turin, Department of Clinical & Biological Sciences, Thoracic Oncology Unit, San Luigi Hospital, Regione Gonzole, Orbassano (Torino), Italy.
Expert Opin Emerg Drugs. 2007 Mar;12(1):127-37. doi: 10.1517/14728214.12.1.127.
Malignant mesothelioma is an aggressive, but relatively rare, malignancy, affecting the pleura and peritoneum. The prognosis for malignant pleural mesothelioma (MPM) is poor, with median survival in the range of 8-14 months, depending on stage and presentation of disease. Long-term results of available treatments are disappointing not only in terms of prognosis, but also of local control of the disease. Therefore, relief of symptoms and improvement of quality of life parameters are the short-term goals of therapy. In advanced disease not amenable to any local approach, such as surgery, combination chemotherapy represents the current standard of care. At present, the regimen of cisplatin/pemetrexed is the medical treatment of choice. This review summarizes standard chemotherapy options and focuses on the molecular basis of the newest biologically targeted therapies to be implemented in the near future, in the management of MPM.
恶性间皮瘤是一种侵袭性但相对罕见的恶性肿瘤，可累及胸膜和腹膜。恶性胸膜间皮瘤（MPM）的预后较差，中位生存期在8至14个月之间，具体取决于疾病的分期和表现。现有治疗方法的长期效果不仅在预后方面令人失望，而且在疾病的局部控制方面也是如此。因此，缓解症状和改善生活质量指标是治疗的短期目标。在无法采用任何局部治疗方法（如手术）的晚期疾病中，联合化疗是目前的标准治疗方法。目前，顺铂/培美曲塞方案是首选的药物治疗方案。本综述总结了标准化疗方案，并重点关注在MPM管理中近期将实施的最新生物靶向治疗的分子基础。
